Sirolimus is not always responsible for new-onset proteinuria after conversion for chronic allograft nephropathy

Pediatric Transplantation

Volumn 11, Issue 3, 2007, Pages 336-339

  Abdurrahman, Zainab ^a   Sarwal, Minnie ^b   Millan, Maria ^b   Robertson, Susan ^c   Filler, Guido ^a,c,d  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

Author keywords

Combined liver and kidney transplantation; Donor specific HLA antibodies; Proteinuria; Sirolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; FOSINOPRIL; HLA ANTIBODY; HLA DR17 ANTIBODY; HLA DR18 ANTIBODY; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULOPATHY; GRAFT REJECTION; HEMODIALYSIS; HLA TYPING; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LOW DRUG DOSE; MALE; OXALOSIS 1; PERITONEAL DIALYSIS; PROTEINURIA; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

BIOPSY; CHILD; CHRONIC DISEASE; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PROTEINURIA; SIROLIMUS;

EID: 34147188537     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00670.x     Document Type: Article

References (21)

1. KREIS HA, PONTICELLI C. Causes of late renal allograft loss: Chronic allograft dysfunction, death, and other factors. Transplantation 2001: 71(Suppl.): SS5-SS9.
2. LEE VW, CHAPMAN JR. Sirolimus: Its role in nephrology. Nephrology (Carlton) 2005: 10: 606-614.
3. MERKEL S, MOGILEVSKAJA N, MENGEL M, HALLER H, SCHWARZ A. Side effects of sirolimus. Transplant Proc 2006: 38: 714-715.
4. RUIZ JC, DIEKMANN F, CAMPISTOL JM, et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005: 37: 3833-3855.
5. BUMBEA V, KAMAR N, RIBES D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005: 20: 2517-2523.
6. FILLER G, WOMILOJU T, FEBER J, et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005: 5: 2005-2010.
7. BORATYNSKA M, BANASIK M, WATOREK E, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006: 38: 101-104.
8. IBANEZ JP, MONTEVERDE ML, GOLDBERG J, DIAZ MA, TURCONI A. Sirolimus in pediatric renal transplantation. Transplant Proc 2005: 37: 682-684.
9. FALGER JC, MUELLER T, ARBEITER K, et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 474-478.
10. STRAATHOF-GALEMA L, WETZELS JF, DIJKMAN HB, STEENBERGEN EJ, HILBRANDS LB. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006: 6: 429-433.
11. SAURINA A, CAMPISTOL JM, PIERA C et al.. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: Changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006: 21: 488-493.
12. IZZEDINE H, BROCHERIOU I, FRANCES C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005: 353: 2088-2089.
13. LUN A, IVANDIC M, PRIEM F, et al. Evaluation of pediatric nephropathies by a computerized Urine Protein Expert System (UPES). Pediatr Nephrol 1999: 13: 900-906.
14. COOMBES JD, MREICH E, LIDDLE C, RANGAN GK. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005: 68: 2599-2607.
15. HERMAN J, LERUT E, VAN DAMME- LOMBAERTS R, EMONDS MP, VAN DAMME B. Capillary deposition of complement C4d and C3d in pediatric renal allograft biopsies. Transplantation 2005: 79: 1435-1440.
16. MJORNSTEDT L, FRIMAN S, BACKMAN L, RYDBERG L, OLAUSSON M. Combined liver and kidney transplantation against a positive cross match in a patient with multispecific HLA-antibodies. Transplant Proc 1997: 29: 3164-3165.
17. PALOMAR R, LOPEZ-HOYOS M, PASTOR JM, et al. Impact of HLA antibodies on transplant glomerulopathy. Transplant Proc 2005: 37: 3830-3832.
18. FERNANDEZ-FRESNEDO G, PASTOR JM, LOPEZ-HOYOS M, et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrol Dial Transplant 2003: 18: 990-995.
19. ALLISON AC, EUGUI EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005: 80(Suppl.): S181-S190.
20. JOOSTEN SA, VAN KOOTEN C, PAUL LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003: 16: 137-145.
21. PIAZZA A, POGGI E, BORRELLI L, et al. Impact of donorspecific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 2001: 71: 1106-1112.